Quick Answer
iSpecimen Inc. reported Stockholders Equity of $3.31 million for the year ending 2024.
- iSpecimen Inc. showed a decrease of -66.0% in Stockholders Equity from 2023 to 2024.
- This data is from iSpecimen Inc.'s annual report (Form 10-K), filed with the SEC on April 14, 2025.
- XBRL data for this metric is available from 2019 to 2024 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$24.33 million | Q2 2020: -$24.48 million | Q3 2020: -$25.70 million | Q1 2021: -$31.22 million | Q2 2021: $10.68 million | Q3 2021: $12.09 million | Q1 2022: $27.67 million | Q2 2022: $25.30 million | Q3 2022: $22.42 million | Q1 2023: $18.08 million | Q2 2023: $14.71 million | Q3 2023: $12.71 million | Q4 2023: $9.74 million | Q1 2024: $6.81 million | Q2 2024: $6.09 million | Q3 2024: $4.71 million | Q4 2024: $3.31 million | Q1 2025: $1.67 million | Q2 2025: $622.0 thousand | Q3 2025: $3.07 million.
- Over the full 6 years of available data (2019 to 2024), iSpecimen Inc.'s Stockholders Equity has grown by 114.6%.
- Historical annual values: Fiscal year 2024: $3.31 million | Fiscal year 2023: $9.74 million | Fiscal year 2022: $20.31 million | Fiscal year 2021: $29.79 million | Fiscal year 2020: -$27.28 million | Fiscal year 2019: -$22.72 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: